Psychotropic medication use during pregnancy: changes to the labeling system and the importance of exposure registries.
In this issue of JCP, Cohen et al present the methodology of the National Pregnancy Registry for Atypical Antipsychotics (NPRAA). In full disclosure, the investigators are my colleagues, and I have great interest in the topic of pregnancy registries, including this particular registry, as a perinatal psychiatrist and from a scientific perspective. Highlighting the importance of this paper is intuitive because we are at a defining moment in the application of data to inform the care of pregnant women.